Imatinib
别名: STI571, CGP-57148B
中文名称:伊马替尼
目录号:S2475 Purity: 99.97%
Imatinib是一种多靶点酪氨酸激酶抑制剂,抑制v-Abl、c-Kit和PDGFR的IC50分别为0.6,0.1和0.1 μM。Imatinib (STI571) 可诱导自噬。
CAS: 152459-95-5
客户使用Selleck的Imatinib发表文献306篇
- Nat Biomed Eng, 2024 10.1038/s41551-024-01204-8
- Mol Cancer, 2023 10.1186/s12943-023-01837-4
- Cell, 2022 S0092-8674(22)00472-X
- Nat Cancer, 2022 3(3):318-336
- Cell Host Microbe, 2021 29(6):941-958.e10
- Nat Metab, 2021 3(5):682-700
- Science, 2020 370(6513)eabc2754
- Cancer Cell, 2020 38(6):872-890.e6
- Cell Host Microbe, 2020 11;27(3):476-485 e7
- J Hematol Oncol, 2020 13(1):80
- Blood, 2020 8 pii: blood
- Cancer Cell, 2019 36(4):431-443
- Cancer Discov, 2019 9(6):756-777
- Cancer Cell, 2018 34(2):271-285.e7
- Cancer Cell, 2018 34(4):626-642
- Nat Biomed Eng, 2018 2(8):578-588
- Blood, 2016 28;127(17):2131-43
- Cancer Cell, 2014 26(6):840-50
- Blood, 2014 123(21):3296-304
- Cancer Discov, 2013 3(5):520-33
- Cell Stem Cell, 2012 10(2):210-7
- Cell Rep Med, 2024 S2666-3791(24)00201-5
- Elife, 2024 12RP92324
- Aging Dis, 2024 15(1):369-389
- Int J Mol Sci, 2024 25(5)2956
- Cancers (Basel), 2024 16(7)1288
- Transl Oncol, 2024 49:102073
- Plants (Basel), 2024 13(9)1201
- Invest Ophthalmol Vis Sci, 2024 65(13):40
- J Cancer, 2024 15(8):2424-2430
- BMC Cancer, 2024 24(1):1200
- J Extracell Biol, 2024 3(1):e139
- Cell Commun Signal, 2023 21(1):342
- Phytomedicine, 2023 117:154918
- NPJ Precis Oncol, 2023 7(1):132
- Elife, 2023 12e79840
- Front Immunol, 2023 14:1078958
- iScience, 2023 26(9):107704
- Cancer Cell Int, 2023 23(1):302
- Int J Mol Sci, 2023 24(1)830
- Front Pharmacol, 2023 14:1183052
- Pharmaceuticals (Basel), 2023 17(1)9
- Molecules, 2023 28(3)1210
- Invest Ophthalmol Vis Sci, 2023 10.1167/iovs.64.14.9
- Biochem Biophys Rep, 2023 33:101403
- bioRxiv, 2023 2023.01.19.524758
- Res Sq, 2023 rs.3.rs-3049913
- Cell Rep Med, 2022 3(1):100492
- Theranostics, 2022 12(16):6972-6988
- Cancer Res, 2022 82-15:2777-2791
- Clin Transl Med, 2022 12(9):e1038
- Clin Transl Med, 2022 12(12):e1146
- Cell Rep, 2022 41(11):111827
- Cell Rep, 2022 39(4):110721
- Elife, 2022 11e74700
- Osteoarthritis Cartilage, 2022 S1063-4584(22)00035-8
- iScience, 2022 25(10):105182
- Int J Mol Sci, 2022 23(17)9587
- Int J Mol Sci, 2022 23(24)16149
- Front Cell Neurosci, 2022 16:941031
- Cancers (Basel), 2022 14(23)5975
- J Pers Med, 2022 12(2)258
- Arthritis Res Ther, 2022 24-1:210
- J Hypertens, 2022 40(10):1935-1949
- J Biol Chem, 2022 299(2):102841
- Biomedicines, 2022 10(5)1158
- Front Oncol, 2022 12:904510
- Front Oncol, 2022 12:901132
- Pharmaceuticals (Basel), 2022 15(9)1111
- J Oncol, 2022 2022:4112016
- Hum Cell, 2022 10.1007/s13577-022-00671-y
- Pharm Biol, 2022 60(1):700-707
- Exp Cell Res, 2022 S0014-4827(22)00212-9
- Ann Surg Oncol, 2022 29(12):7354-7367
- Birth Defects Res, 2022 10.1002/bdr2.2001
- Int J Hematol, 2022 10.1007/s12185-022-03369-x
- Sci Adv, 2022 8(6):eabg9455
- ProQuest, 2022 29064559
- Magn Reson (Gott), 2022 3(1):91-99
- Animal Model Exp Med, 2022 10.1002/ame2.12282
- Nat Commun, 2021 12(1):51
- Clin Cancer Res, 2021 27(9):2533-2548
- Cancer Res, 2021 canres.1153.2021
- Cancer Res, 2021 81(21):5438-5450
- Genes Dev, 2021 10.1101/gad.348667.121
- Cell Death Dis, 2021 12(4):367
- Cell Death Dis, 2021 12(5):456
- Cell Rep, 2021 37(1):109788
- Cell Chem Biol, 2021 S2451-9456(21)00303-2
- Elife, 2021 10e68466
- Cell Death Discov, 2021 7(1):139
- Clin Sci (Lond), 2021 135(19):2243-2263
- J Clin Endocrinol Metab, 2021 dgab020
- Biochem Pharmacol, 2021 190:114658
- Front Cell Dev Biol, 2021 9:643043
- Front Cell Dev Biol, 2021 9:695225
- CNS Neurosci Ther, 2021 10.1111/cns.13708
- Cancers (Basel), 2021 13(14)3635
- Hum Cell, 2021 10.1007/s13577-021-00639-4
- Hum Cell, 2021 34(6):1911-1918
- Hum Cell, 2021 10.1007/s13577-021-00579-z
- World J Gastroenterol, 2021 27(32):5392-5403
- Ann Hematol, 2021 10.1007/s00277-020-04357-z
- Hum Mol Genet, 2021 ddab011
- Hum Mol Genet, 2021 ddab014
- Cell Microbiol, 2021 e13398
- Invest New Drugs, 2021 10.1007/s10637-020-01028-8
- Exp Ther Med, 2021 22(1):735
- Am J Med Genet A, 2021 10.1002/ajmg.a.62603
- Nat Commun, 2020 11(1):5060
- Genome Med, 2020 18;12(1):17
- Clin Cancer Res, 2020 21;clincanres31422019
- Cancer Res, 2020 canres.1992.2020
- Proc Natl Acad Sci U S A, 2020 117(8):4300-4309
- Cancer Lett, 2020 469:195-206
- Cell Rep, 2020 33(1):108221
- Cell Rep, 2020 24;30(12):3951-3963 e4
- Br J Cancer, 2020 10.1038/s41416-020-0952-1
- Mol Cell Proteomics, 2020 10.1074/mcp.RA119.001504
- PLoS Pathog, 2020 16(8):e1008823
- Antioxid Redox Signal, 2020 32(1):35-59
- Hemasphere, 2020 4(6):e497
- Commun Biol, 2020 3(1):18
- Cancer Cell Int, 2020 19;20:58
- Front Bioeng Biotechnol, 2020 20;8:482
- Am J Physiol Cell Physiol, 2020 10.1152/ajpcell.00290.2020
- Am J Cancer Res, 2020 10(12):4251-4265
- Cancers (Basel), 2020 25;12(5)
- Cancers (Basel), 2020 13;12(2) pii: E436
- Ann N Y Acad Sci, 2020 1467(1):77-93
- Aging (Albany NY), 2020 12(17):17662-17680
- J Pers Med, 2020 10(4)E234
- FASEB J, 2020 34(3):3773-3791
- Front Aging Neurosci, 2020 12:7
- Front Oncol, 2020 12;10:696
- Sci Rep, 2020 10(1):11269
- Hum Cell, 2020 10.1007/s13577-020-00425-8
- Hum Cell, 2020 10.1007/s13577-020-00420-z
- Oncol Rep, 2020 44(5):2152-2164
- Front Physiol, 2020 11:555006
- J Cell Sci, 2020 11 pii: jcs
- Micromachines (Basel), 2020 11(2)
- J Pharm Biomed Anal, 2020 195:113864
- J Mol Neurosci, 2020 10.1007/s12031-020-01735-0
- Biochem Biophys Res Commun, 2020 529(3):699-706
- Biochim Biophys Acta Gen Subj, 2020 1864(4):129507
- Sci Adv, 2020 6(33):eaaz8850
- bioRxiv, 2020 2020/9/20.4.7.30734
- Cold Spring Harb Mol Case Stud, 2020 mcs.a005710
- Nat Commun, 2019 10(1):2204
- J Clin Invest, 2019 129(3):1167-1179
- J Exp Med, 2019 216(3):688-703
- Dev Cell, 2019 51(2):236-254
- J Exp Clin Cancer Res, 2019 18;38(1):85
- J Control Release, 2019 310:141-154
- Haematologica, 2019 10.3324/haematol.2019.215939
- Cell Rep, 2019 28(9):2331-2344
- Thyroid, 2019 29(5):674-682
- Hum Reprod, 2019 34(3):506-518
- Mol Cancer Ther, 2019 18(6):1137-1148
- Mol Cancer Ther, 2019 18(11):1985-1996
- J Cell Mol Med, 2019 23(12):8314-8327
- Eur J Hum Genet, 2019 27(4):574-581
- Neuropharmacology, 2019 149:13-26
- Molecules, 2019 24(3)
- Molecules, 2019 25(1)
- Med Oncol, 2019 36(3):30
- Mol Med Rep, 2019 20(4):3233-3239
- Cancer Manag Res, 2019 11:5197-5208
- Biochem Biophys Res Commun, 2019 512(4):871-876
- Prostate, 2019 79(3):259-264
- Leuk Res, 2019 78:12-20
- Leuk Lymphoma, 2019 60(1):189-199
- Res Vet Sci, 2019 124:1-9
- Cancer Invest, 2019 37(6):242-252
- Anticancer Res, 2019 39(7):3785-3793
- Sci Adv, 2019 5(2):eaau7130
- bioRxiv, 2019 10.1101/680165
- Nat Commun, 2018 9(1):2377
- Nat Commun, 2018 9(1):4583
- Acta Neuropathol, 2018 135(5):779-798
- J Exp Clin Cancer Res, 2018 25;37(1):170
- Oncogene, 2018 37(21):2837-2849
- Elife, 2018 7e36656
- Biomed Pharmacother, 2018 106:403-410
- Front Immunol, 2018
- Cell Death Discov, 2018 4:48
- Hemasphere, 2018 2(3):e41
- Am J Respir Cell Mol Biol, 2018 58(2):181-193
- Int J Cancer, 2018 142(1):156-164
- Biochem Pharmacol, 2018 156:248-264
- Cancer Sci, 2018 109(11):3591-3601
- Mol Cancer Ther, 2018 17(7):1526-1539
- Mol Cancer Ther, 2018 17(12):2551-2563
- Cancer Sci, 2018 109(9):2792-2800
- J Cell Physiol, 2018 233(9):7467-7479
- Oncotarget, 2018 9(100):37352-37366
- Int J Oncol, 2018 52(6):2061-2068
- Mol Cancer Res, 2018 16(6):935-946
- Am J Physiol Lung Cell Mol Physiol, 2018 315(6):L965-L976
- Neoplasia, 2018 20(8):857-870
- Molecules, 2018 23(10)
- Sci Rep, 2018 8(1):14896
- Oncol Rep, 2018 40(2):902-908
- Endocr Relat Cancer, 2018 25(4):471-480
- PLoS One, 2018 13(2):e0191890
- BMC Pharmacol Toxicol, 2018 19(1):80
- J Assoc Res Otolaryngol, 2018 19(4):363-379
- Int J Clin Exp Pathol, 2018 11(1):179-188
- Nat Commun, 2017 8(1):1420
- Leukemia, 2017 31(11):2376-2387
- Cancer Res, 2017 77(5):1142-1154
- Cancer Res, 2017 77(20):5554-5563
- Cancer Lett, 2017 395:20-30
- Cell Death Dis, 2017 8(10):e3117
- Cell Rep, 2017
- Cell Rep, 2017 20(12):2775-2783
- Cell Chem Biol, 2017 24(7):858-869
- Cell Chem Biol, 2017 24(10):1250-1258.e4
- Oncogene, 2017 36(15):2066-2073
- Elife, 2017 6
- Blood Adv, 2017 1(20):1635-1644
- Arch Toxicol, 2017 91(8):2921-2938
- Mol Cancer Ther, 2017 16(9):1729-1738
- Oncotarget, 2017 8(14):23213-23227
- Oncotarget, 2017 8(27):43662-43677
- Oncotarget, 2017 8(17):28906-28921
- Oncotarget, 2017 8(23):37594-37604
- Mol Pharm, 2017 14(10):3558-3567
- Drug Des Devel Ther, 2017 11:1115-1126
- J Biol Chem, 2017 292(9):3683-3691
- J Biol Chem, 2017
- Bioconjug Chem, 2017 28(10):2608-2619
- Molecules, 2017 22(12)
- Sci Rep, 2017
- BMC Cancer, 2017
- PLoS One, 2017 12(7):e0180401
- PLoS One, 2017 12(5):e0177871
- Invest New Drugs, 2017 35(4):427-435
- Dig Dis Sci, 2017 62(5):1193-1203
- SLAS Discov, 2017 22(7):915-922
- Leuk Lymphoma, 2017 58(6):1455-1467
- Leuk Lymphoma, 2017 58(8):1903-1913
- Zhonghua Xue Ye Xue Za Zhi, 2017 38(12):1036-1042
- J Clin Invest, 2016 126(10):3961-3980
- EMBO Mol Med, 2016 1;8(2):105-16
- Mol Cancer Ther, 2016 15(10):2302-2313
- Oncotarget, 2016 7(29):45916-45925
- Oncotarget, 2016 7(34):54583-54595
- Oncotarget, 2016 7(18):26709-23
- Transl Oncol, 2016 9(6):540-547
- Am J Physiol Lung Cell Mol Physiol, 2016 311(2):L364-74
- Cell Signal, 2016 28(10):1489-501
- Traffic, 2016 17(4):351-68
- Pharmacol Rep, 2016 68(1):1-6
- Oncol Rep, 2016 36(6):3643-3650
- Upsala Journal of Medical Sciences, 2016 140-145
- Ups J Med Sci, 2016 121(2):140-5
- Cell Biochem Biophys, 2016 74(2):277-83
- Genes Cancer, 2016 7(9-10):292-300
- Nat Commun, 2015 6:8481
- Nat Commun, 2015 6:7002
- Cell Rep, 2015 11(1):98-110
- Oncogene, 2015 10.1038/onc.2015.111
- J Med Chem, 2015 58(23):9228-37
- J Urol, 2015 194(6):1797-805
- Cancer Sci, 2015 106(2):160-70
- Sci Rep, 2015 5:9775
- Exp Cell Res, 2015 332(1):1-10
- Oncol Lett, 2015 10(5):2835-2841
- Leuk Res, 2015 39(3):355-60
- Leuk Res, 2015 10.1016/j.leukres.2015.08.007
- Leukemia, 2014 28(4):977-9
- Elife, 2014 3:e02523
- Thrombo Res, 2014 135(1):155-60
- Sci Signal, 2014 7(322):ra38
- Mol Oncol, 2014 8(5):968-81
- Mol Cancer Ther, 2014 13(6):1664-72
- Oncotarget, 2014 5(7):1926-41
- Stem Cells, 2014 32(9):2324-37
- J Alzheimers Dis, 2014 41(3):729-37
- Drug Metab Dispos, 2014 42(3):318-22
- PLoS One, 2014 9(1):e84900
- PLoS One, 2014 9(3):e91782
- Mol Med Rep, 2014 10(3):1519-24
- Biochem Biophys Res Commun, 2014 455(3-4):256-61
- Leuk Lymphoma, 2014 22:1-8
- BMC Vet Res, 2014 10:105
- Biol Pharm Bull, 2014 37(8):1330-5
- Harbin Medical University, 2014 Wang GY
- Oncoscience, 2014 1(1):57-68
- Clin Cancer Res, 2013 19(9):2381-92
- Clin Cancer Res, 2013 19(24):6935-42
- PLoS Biol, 2013 11(3):e1001515
- Apoptosis, 2013 18(11):1437-1446
- Apoptosis, 2013 18(9):1060-70
- Int J Mol Med, 2013 31(2):453-8
- Transl Oncol, 2013 6(2):187-96
- Leuk Lymphoma, 2013 54(2):342-52
- Biomed Chromatogr, 2013 27(4):502-8
- J Virol, 2012 86(18):10112-22
- Leuk Res, 2012 37(2):183-9
- Cell Death Dis, 2011 2:e170
- Clin Pharmacol Ther, 2011 90(1):157-63
- FASEB J, 2011 25(10):3661-73
- PLoS One, 2010 5(11):e14143
化学信息&溶解度
分子量 | 493.6 |
分子式 | C29H31N7O |
CAS号 | 152459-95-5 |
Smiles | CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5 |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 25 mg/mL ( 50.64 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 25 mg/mL ( 50.64 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 23 mg/mL ( 46.59 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
2%DMSO
30%PEG300
2%Tween80
66%ddH2O
浓度:2mg/ml
(4.05mM)
操作示例:以 1 mL 工作液为例,取20μL100mg/ml的澄清DMSO储备液加到300μL PEG300中,混合均匀使其澄清;向上述体系中加入20μLTween80,混合均匀使其澄清;然后继续加入660μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。